tetano
Editor, Senior Moderator
Vaccines (Basel). 2019 May 28;7(2). pii: E46. doi: 10.3390/vaccines7020046.
[h=1]Bacterial Outer Membrane Vesicles (OMVs)-based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV.[/h] Shehata MM[SUP]1[/SUP], Mostafa A[SUP]2,[/SUP][SUP]3[/SUP], Teubner L[SUP]4[/SUP], Mahmoud SH[SUP]5[/SUP], Kandeil A[SUP]6[/SUP], Elshesheny R[SUP]7[/SUP], Frantz R[SUP]8[/SUP], Pietra L[SUP]9[/SUP], Pleschka S[SUP]10[/SUP], Osman A[SUP]11[/SUP], Kayali G[SUP]12,[/SUP][SUP]13[/SUP], Chakraborty T[SUP]14[/SUP], Ali MA[SUP]15[/SUP], Mraheil MA[SUP]16[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination is the most functional medical intervention to prophylactically control severe diseases caused by human-to-human or animal-to-human transmissible viral pathogens. Annually, seasonal influenza epidemics attack human populations leading to 290-650 thousand deaths/year worldwide. Recently, a novel Middle East Respiratory Syndrome Coronavirus emerged. Together, those two viruses present a significant public health burden in areas where they circulate. Herein, we generated a bacterial outer membrane vesicles (OMVs)-based vaccine presenting the antigenic stable chimeric fusion protein of the H1-type haemagglutinin (HA) of the pandemic influenza A virus (H1N1) strain from 2009 (H1N1pdm09) and the receptor binding domain (RBD) of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (OMVs-H1/RBD). Our results showed that the chimeric antigen could induce specific neutralizing antibodies against both strains leading to protection of immunized mice against H1N1pdm09 and efficient neutralization of MERS-CoV. This study demonstrate that OMVs-based vaccines presenting viral antigens provide a safe and reliable approach to protect against two different viral infections.
[h=4]KEYWORDS:[/h] H1N1pdm; MERS-CoV; OMVs; influenza vaccine
PMID: 31141982 DOI: 10.3390/vaccines7020046
[h=1]Bacterial Outer Membrane Vesicles (OMVs)-based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV.[/h] Shehata MM[SUP]1[/SUP], Mostafa A[SUP]2,[/SUP][SUP]3[/SUP], Teubner L[SUP]4[/SUP], Mahmoud SH[SUP]5[/SUP], Kandeil A[SUP]6[/SUP], Elshesheny R[SUP]7[/SUP], Frantz R[SUP]8[/SUP], Pietra L[SUP]9[/SUP], Pleschka S[SUP]10[/SUP], Osman A[SUP]11[/SUP], Kayali G[SUP]12,[/SUP][SUP]13[/SUP], Chakraborty T[SUP]14[/SUP], Ali MA[SUP]15[/SUP], Mraheil MA[SUP]16[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination is the most functional medical intervention to prophylactically control severe diseases caused by human-to-human or animal-to-human transmissible viral pathogens. Annually, seasonal influenza epidemics attack human populations leading to 290-650 thousand deaths/year worldwide. Recently, a novel Middle East Respiratory Syndrome Coronavirus emerged. Together, those two viruses present a significant public health burden in areas where they circulate. Herein, we generated a bacterial outer membrane vesicles (OMVs)-based vaccine presenting the antigenic stable chimeric fusion protein of the H1-type haemagglutinin (HA) of the pandemic influenza A virus (H1N1) strain from 2009 (H1N1pdm09) and the receptor binding domain (RBD) of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) (OMVs-H1/RBD). Our results showed that the chimeric antigen could induce specific neutralizing antibodies against both strains leading to protection of immunized mice against H1N1pdm09 and efficient neutralization of MERS-CoV. This study demonstrate that OMVs-based vaccines presenting viral antigens provide a safe and reliable approach to protect against two different viral infections.
[h=4]KEYWORDS:[/h] H1N1pdm; MERS-CoV; OMVs; influenza vaccine
PMID: 31141982 DOI: 10.3390/vaccines7020046